---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-23-000035"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:55:51.727164+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal raises FY 2023 guidance after Q3 prelim: rev $610-620M, adj EBITDA $150-155M

## Summary
- Net revenue prelim Q3 2023 $610-620M, up ~13% YoY.
- Adjusted EBITDA $150-155M, up ~21% YoY; income before taxes $18-28M, substantially higher YoY.
- Net leverage declined to ~4.6x from 5.3x at Dec 2022 due to higher profitability and debt reduction.
- Full-year 2023 guidance raised; Co-CEOs cite momentum from generics, biosimilars, and AvKARE.
- IPX203 for Parkinson's on track for potential 2024 launch.

## SEC filing metadata
- accession: 0001723128-23-000035
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/0001723128-23-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/amrx-20231023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-23-000035
- JSON: https://secwatch.observer/filing/0001723128-23-000035.json
- Plain text: https://secwatch.observer/filing/0001723128-23-000035.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: revenue $610 million to $620 million. Guidance raised.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $610 million to $620 million
  - Guidance: raised
  - Result: preliminary results
  source text: report actual third quarter 2023 financial results on November 7, 2023. Unaudited Preliminary Financial Results for the Third Quarter Ended September 30, 2023 • Net revenue of $610 million to $620 million, an increase of approximately 13% compared to the third quarter of 2022 • Income before income taxes of $18 million to $28 million, which is substantially higher
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/0001723128-23-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.